Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 3,187 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $23.63, for a total transaction of $75,308.81. Following the completion of the sale, the executive vice president directly owned 169,203 shares in the company, valued at $3,998,266.89. This represents a 1.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $23.84 on Friday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $29.78. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. The company has a fifty day moving average of $20.48 and a two-hundred day moving average of $20.59. The stock has a market capitalization of $1.01 billion, a PE ratio of 14.11, a P/E/G ratio of 4.57 and a beta of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. As a group, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent research reports. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Wells Fargo & Company upped their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Bank of America reiterated an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $22.50.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AMPH. AQR Capital Management LLC boosted its stake in Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after buying an additional 24,167 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after acquiring an additional 613 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock worth $1,748,000 after acquiring an additional 18,133 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $1,865,000. Finally, Invesco Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 7.7% during the 2nd quarter. Invesco Ltd. now owns 386,971 shares of the company’s stock worth $8,885,000 after purchasing an additional 27,828 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.